318 related articles for article (PubMed ID: 21455855)
1. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
Zamagni E; Brioli A; Tacchetti P; Zannetti B; Pantani L; Cavo M
Semin Thromb Hemost; 2011 Apr; 37(3):209-19. PubMed ID: 21455855
[TBL] [Abstract][Full Text] [Related]
2. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Palumbo A; Rajkumar SV; Dimopoulos MA; Richardson PG; San Miguel J; Barlogie B; Harousseau J; Zonder JA; Cavo M; Zangari M; Attal M; Belch A; Knop S; Joshua D; Sezer O; Ludwig H; Vesole D; Bladé J; Kyle R; Westin J; Weber D; Bringhen S; Niesvizky R; Waage A; von Lilienfeld-Toal M; Lonial S; Morgan GJ; Orlowski RZ; Shimizu K; Anderson KC; Boccadoro M; Durie BG; Sonneveld P; Hussein MA;
Leukemia; 2008 Feb; 22(2):414-23. PubMed ID: 18094721
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin.
Cini M; Zamagni E; Valdré L; Palareti G; Patriarca F; Tacchetti P; Legnani C; Catalano L; Masini L; Tosi P; Gozzetti A; Cavo M
Eur J Haematol; 2010 Jun; 84(6):484-92. PubMed ID: 20192986
[TBL] [Abstract][Full Text] [Related]
4. Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy.
Musallam KM; Dahdaleh FS; Shamseddine AI; Taher AT
Thromb Res; 2009 Mar; 123(5):679-86. PubMed ID: 18992924
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis.
Anaissie EJ; Coleman EA; Goodwin JA; Kennedy RL; Lockhart KD; Stewart CB; Coon SK; Bailey C; Barlogie B
Cancer; 2012 Jan; 118(2):549-57. PubMed ID: 21720994
[TBL] [Abstract][Full Text] [Related]
6. A retrospective cohort study of venous thromboembolism(VTE) in 1035 Japanese myeloma patients treated with thalidomide; lower incidence without statistically significant association between specific risk factors and development of VTE and effects of thromboprophylaxis with aspirin and warfarin.
Kato A; Takano H; Ichikawa A; Koshino M; Igarashi A; Hattori K; Nagata K
Thromb Res; 2013 Feb; 131(2):140-4. PubMed ID: 23232090
[TBL] [Abstract][Full Text] [Related]
7. Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations.
Hussein MA
Thromb Haemost; 2006 Jun; 95(6):924-30. PubMed ID: 16732369
[TBL] [Abstract][Full Text] [Related]
8. Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis.
Uaprasert N; Voorhees PM; Mackman N; Key NS
Eur J Cancer; 2010 Jul; 46(10):1790-9. PubMed ID: 20385482
[TBL] [Abstract][Full Text] [Related]
9. Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone.
Klein U; Kosely F; Hillengass J; Hundemer M; Schmitt S; Neben K; Moehler T; Hegenbart U; Ho AD; Goldschmidt H
Ann Hematol; 2009 Jan; 88(1):67-71. PubMed ID: 18668241
[TBL] [Abstract][Full Text] [Related]
10. Thrombosis in multiple myeloma.
Zangari M; Elice F; Fink L; Tricot G
Expert Rev Anticancer Ther; 2007 Mar; 7(3):307-15. PubMed ID: 17338651
[TBL] [Abstract][Full Text] [Related]
11. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.
Zangari M; Fink L; Zhan F; Tricot G
Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):228-36. PubMed ID: 21575928
[TBL] [Abstract][Full Text] [Related]
12. Management of treatment-related adverse events in patients with multiple myeloma.
Mateos MV
Cancer Treat Rev; 2010 May; 36 Suppl 2():S24-32. PubMed ID: 20472185
[TBL] [Abstract][Full Text] [Related]
13. MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs.
Leleu X; Rodon P; Hulin C; Daley L; Dauriac C; Hacini M; Decaux O; Eisemann JC; Fitoussi O; Lioure B; Voillat L; Slama B; Al Jijakli A; Benramdane R; Chaleteix C; Costello R; Thyss A; Mathiot C; Boyle E; Maloisel F; Stoppa AM; Kolb B; Michallet M; Lamblin A; Natta P; Facon T; Elalamy I; Fermand JP; Moreau P
Thromb Haemost; 2013 Oct; 110(4):844-51. PubMed ID: 23903204
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide and thrombosis. A meta-analysis.
El Accaoui RN; Shamseddeen WA; Taher AT
Thromb Haemost; 2007 Jun; 97(6):1031-6. PubMed ID: 17549307
[TBL] [Abstract][Full Text] [Related]
15. Low incidence of thromboembolism in relapsed/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan.
Wu SY; Yeh YM; Chen YP; Su WC; Chen TY
Ann Hematol; 2012 Nov; 91(11):1773-8. PubMed ID: 22706703
[TBL] [Abstract][Full Text] [Related]
16. Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review.
Al-Ani F; Bermejo JM; Mateos MV; Louzada M
Thromb Res; 2016 May; 141():84-90. PubMed ID: 26986753
[TBL] [Abstract][Full Text] [Related]
17. Update of thrombosis in multiple myeloma.
Leebeek FW
Thromb Res; 2016 Apr; 140 Suppl 1():S76-80. PubMed ID: 27067983
[TBL] [Abstract][Full Text] [Related]
18. Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital.
Alexander M; Teoh KC; Lingaratnam S; Kirsa S; Mellor JD
Asia Pac J Clin Oncol; 2013 Jun; 9(2):169-75. PubMed ID: 22998589
[TBL] [Abstract][Full Text] [Related]
19. Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials.
Thaler J; Ay C; Pabinger I
Thromb Haemost; 2012 Dec; 108(6):1042-8. PubMed ID: 22836491
[TBL] [Abstract][Full Text] [Related]
20. VTE prophylaxis for the medical patient: where do we stand? - a focus on cancer patients.
Cohen AT; Nandini B; Wills JO; Ota S
Thromb Res; 2010 Apr; 125 Suppl 2():S21-9. PubMed ID: 20434000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
